-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK

Benzinga·06/02/2025 11:09:45
Listen to the news

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK.